Start here
Where are you in your journey?
Choose the path that fits today. We’ll take you to the most useful discussions.
- GLP-1 medication Zepbound, Wegovy, access, side effects, progress, and support.
- Before surgery Compare procedures, plan ahead, and get honest pre-op answers.
- Post-op Recovery, food stages, symptoms, and support.
- Long-term Regain, labs, habits, and life after the honeymoon.
- Revision Explore revision options, complications, and next steps.
Obesity Treatment News
The latest on bariatric surgery and GLP-1 medicines, written for patients and the clinicians who treat them.
-
UCSF chart review: arriving on a GLP-1 did not change one-year post-op weight results
Among 383 primary bariatric cases from 2022-2024, people who arrived on a GLP-1 matched peers on 12-month total weight loss after adjustment.
-
Among U.S. teens and young adults treated for obesity, GLP-1-only care rose as surgery share fell.
UT Southwestern's Epic Cosmos look at more than 204,000 people ages 13 to 25 was summarized July 20, 2026.
-
FDA approved Foundayo, a once-daily orforglipron tablet, as another oral GLP-1 option.
Lilly's small-molecule pill cleared on April 1, 2026 after a 50-day national-priority review.
-
FDA cleared Wegovy HD 7.2 mg. It is a higher weekly shot, not a new drug class.
The agency approved Novo Nordisk's higher-dose semaglutide injection on March 19, 2026 under a 54-day priority voucher review.